Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lung Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lung Cancer
    Gefitinib Approved in EU for Locally Advanced, Metastatic NSCLC - (DGNews)
    TopAbstracts in Lung Cancer 06/24/2009 - (DGNews)
    TopAbstracts in Lung Cancer 06/10/2009 - (DGNews)
    Prophylactic Cranial Irradiation Has No Impact on Overall Survival in Patients With NSCLC Brain Metastases: Presented at ASCO - (DGDispatch)
    Vandetanib Plus Docetaxel Combination Prolongs Progression-Free Survival in Patients With Non-Small-Cell Lung Cancer: Presented at ASCO - (DGDispatch)

    News archive

     Recent webcasts/CME - Lung Cancer
  • Latest Data From Chicago Provide New Insight Into the Evolving Role of Cytotoxic and Targeted Therapies in Early-Stage NSCLC
  • Silica-Related Lung Disease: It's Still Here

    Webcasts/CME archive

     Recent cases - Lung Cancer
      Diffuse Interstitial Lung Disease Related to Peribronchiolar Metaplasia
      Isolated Pancreatic Metastases from a Bronchogenic Small Cell Carcinoma
      High-Resolution Computed Tomography Illustrating Pulmonary Lymphangitic Carcinomatosis in a Patient with Advanced Pancreatic Cancer: A Case Report
      Mesothelioma in an HIV/AIDS Patient Without History of Asbestos Exposure: Possible Role For Immunosuppression in Mesothelioma: A Case Report
      Pulmonary Lymphoma Mimicking Metastases: A Case Report

      Cases archive
        




      my personal edition > lung cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Implementation Trial results With Docetaxel Closely Mirror What has been seen in past Phase 2 and 3 Trials: Presented at ERS

      By Cameron Johnston

      GLASGOW, SCOTLAND -- September 8, 2004 -- A large implementation study involving patients with non-small-cell lung cancer (NSCLC) who were treated with docetaxel suggests that investigators who have conducted previous phase 2 and 3 trials with the drug might have been too cautious in selecting patients for their research.

      According to principal investigator Céline Mascaux, MD, research fellow at the Jules Bordet Institute, Brussels, Belgium, the previous phase 2 and 3 trials exclude large numbers of patients because they were deemed, for one reason or another, to be ineligible. "They are highly selective about the patients they use in these trials," she said in an interview.

      However, in the latest study, patients were allowed to use docetaxel as long as their performance scores warranted it and they were healthy enough to tolerate the regimen. In the study, 27 patients who had previously failed a platinum-based therapy were compared against the selection criteria for 8 other phase 2 and 3 trials and they were classified as to whether they would have been eligible or ineligible for those studies.

      Patients were then treated with either 75 of 100 mg/m2 of docetaxel.

      The study revealed that in this real-life situation, median survival time was more or less comparable to what was seen in the phase 2 and 3 studies (25 weeks), as was the objective response rate (7.4%). This indicates that many patients who were excluded from the original studies could have been treated because the response rates were similar, Dr. Mascaux said.

      It is important to find that patients showed the same response in this study as what was seen in other studies because it indicates that many more patients may be candidates for docetaxel treatment, even if it is just as salvage therapy, she said. Also, it suggests that the recruitment criteria for many phase 2 and 3 studies are too strict and that patients are unfairly excluded, she added.

      Dr. Mascaux said the argument between phase 2 and 3 studies and real-life implementation studies is not new, but these results demonstrate that as far as the Jules Bordet Institute is concerned, the outcomes in real-life studies are very close to what has been seen in previous clinical trials.

      She added that implementation studies are now the norm at the Institute and that patients who are being treated for NSCLC will be selected on the basis of their Karnofsky performance scores, whether they are strong enough to tolerate any form of chemotherapy, and their own preference as to whether they want to undergo further therapy, given that they have already failed at least one course of a previous treatment.


      [Presentation title: "Implementation Study: Role of Docetaxel After a First Line Cisplatinum Based Chemotherapy For Non-Small Cell Lung Cancer (NSCLC)." Poster 1945]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send